Abstract
Imatinib, an antineoplastic drug used to treat certain cancers, has many side effects such as hematologic, neurologic or cutaneous toxicity. These toxicities seem to be due to a high imatinib plasmatic concentration and are frequently controlled by a discontinuation or a dosage reduction of the drug. We report here in 2 cases of cutaneous side effects induced by imatinib in order to demonstrate the necessity of drug monitoring in such cases. In our cases, imatinib is responsible in the occurrence of these side effects. Monitoring plasma levels of imatinib allowed us to judge if levels were toxic or not and to avoid discontinuation of imatinib in some cases.
Keywords:
cutaneous side effect; imatinib.
Publication types
-
Case Reports
-
English Abstract
MeSH terms
-
Aged
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / blood
-
Benzamides / adverse effects*
-
Benzamides / blood*
-
Benzamides / therapeutic use
-
Drug Eruptions / blood
-
Drug Eruptions / complications
-
Drug Eruptions / etiology
-
Drug Eruptions / therapy*
-
Exanthema / blood
-
Exanthema / chemically induced*
-
Exanthema / complications
-
Exanthema / therapy*
-
Female
-
Humans
-
Imatinib Mesylate
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
-
Male
-
Middle Aged
-
Piperazines / adverse effects*
-
Piperazines / blood*
-
Piperazines / therapeutic use
-
Pruritus / chemically induced
-
Pruritus / complications
-
Pruritus / therapy
-
Pyrimidines / adverse effects*
-
Pyrimidines / blood*
-
Pyrimidines / therapeutic use
Substances
-
Antineoplastic Agents
-
Benzamides
-
Piperazines
-
Pyrimidines
-
Imatinib Mesylate